Improvements in gross motor function were noted in three children, three months after the infusion. Most of the participants, monitored for a year, showed typical developmental progress for children with cerebral palsy.
#Typo pencil case trial#
The phase I clinical trial involved 12 participants, aged 1–16 years, from across Australia who received a sibling's cord blood cells and was followed up for 12 months after the infusion. "Our study found infusing matched sibling cord blood cells into children with cerebral palsy is a relatively safe procedure however it should only be conducted in tertiary hospitals with facilities to treat the infrequent adverse reactions," she said. Kylie Crompton said while there was no cure for cerebral palsy, cord blood cells have the potential to improve brain injury and gross motor function because of their ability to activate repair processes and regenerate some tissues in the human body. All adverse reactions were treated effectively in hospital. Only one serious adverse reaction related to the study was reported, while six of the 12 participants experienced minor adverse reactions.
The study was funded by the Cerebral Palsy Alliance Research Foundation and Cell Care cord blood bank. The clinical trial, led by the Murdoch Children's Research Institute (MCRI) and published in Cytotherapy, stated fully matched umbilical cord blood cells from one child could safely be infused into a sibling with cerebral palsy.
0 kommentar(er)
